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Introduction
Screening for prostate cancer (PCa) leads to a reduction 
in PCa-related mortality as shown in the ERSPC trial (1). 
However, screening also results in relatively large number of 
men being diagnosed with Gleason grade 3+3=6 cancer (2). 
These men typically have a very low risk of dying due to 
PCa, and hence many of these cancers may be considered 
overdiagnosed. In these men active surveillance (AS) is 
typically proposed as a treatment option (3). AS consists of 
closely monitoring the disease status of the patient using 
clinical work up and repeat biopsies to detect a possible 
disease reclassification. If a disease reclassification is 
observed, curative treatment may often be initiated. Several 
simulation studies have shown benefit of AS compared to 
immediate treatment for some patient groups (4-6).
Commonly used surveillance tools in AS are prostate-
specific antigen (PSA), digital rectal exam (DRE) and 
follow-up biopsies (7). Follow-up biopsies are burdensome 
diagnostic tests which have the additional risk of infection 
and/or bleeding (8). Therefore it would be desirable to 
minimize the number of biopsies. On the other hand, 
biopsies are currently the reference standard in detecting 
disease reclassification in AS. Omitting biopsies may lead 
to too late detection of disease reclassification, potentially 
foregoing the window of opportunity for curative treatment.
A promising alternative to fixed protocols for AS is 
risk based, dynamic monitoring. Consider for instance 
that we have two hypothetical patients who have been 
followed for nine months with PSA measurements every 
three months and are scheduled to receive a biopsy at 
12 months (Figure 1). Patient A shows a stable PSA around 
1 ng/mL and consequently has a very low risk of showing 
disease reclassification at 12 months. Patient B shows a 
fast rising PSA and has a relatively high risk of disease 
reclassification. For patient A it may be preferable to 
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defer the biopsy to a later time point in AS, while patient 
B might opt for an earlier biopsy. The use of prediction 
models makes it possible to give risk estimates based on 
information collected during AS and potentially allow for 
such individualized schedules.
Our aim was to compare current fixed schedules with 
risk-based, dynamic monitoring and to discuss proposed 
prediction models which may be used in risk-based follow-up 
during AS. 
Current surveillance schedules and stopping 
criteria
A recent review compared guidelines on AS schedules 
developed by different medical associations (7). Moreover, 
the Movember AS database comprises patients from all 
major studies on AS from all over the world. An overview 
of patient characteristics in the GAP3 database and on 
overview of selection criteria, monitoring tools and 
surveillance schedules has been published recently (9).
Here we present a short overview of currently 
recommended monitoring tools and surveillance schedules 
mentioned in different clinical guidelines as developed by 
medical associations and research cohorts. The previous 
reviews identified several surveillance methods during AS, 
namely serum PSA measurements, DRE, repeat biopsy 
sampling, PSA kinetics, and MRI (Table 1).
Serum PSA measurements
All guidelines that mention follow-up criteria include 
recommendations to use serum PSA measurements 
as a monitoring tool during follow-up. The NCCN, 
KCE, CCNS and PCT guidelines mention that PSA 
measurements should be implemented with intervals 
of at most 6 months. Additionally the PCT guidelines 
recommend doing a PSA measurement every three months 
whenever there is a concern over PSA progression. Three 
guidelines recommend to do PSA measurements every 
3–6 months. Four guidelines (NICE, GSU, SCAN, I+CS) 
use intervals based on the duration of being on AS, typically 
they recommend PSA testing every 3 months when starting 
AS and every 6 months after 1–2 years on AS. Most cohorts 
included in Movember AS database recommend to perform 
PSA testing every 3–6 months, four cohorts recommend the 
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Figure 1 Hypothetical PSA profile and risk of progression for two hypothetical patients. PSA, prostate-specific antigen.
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Table 1 Summary of monitoring tools, timing of monitoring tools and criteria for switching to definitive therapy
Category Monitoring tools Triggers for definitive therapy
Follow-up monitoring and triggers for definitive therapy recommendations in guidelines
Guideline
EAU (10) Serum PSA, DRE and rebiopsy mentioned NR***
NCCN (11) Serum PSA ≤6 months, unless clinically indicated, DRE ≤12 months 
unless clinically indicated, rebiopsy ≤12 months unless clinically 
indicated or at 6 months if the initial biopsy sample had <10 cores, 
MRI mentioned
Rebiopsy sample GS contains grade 4 or 
5 disease, increased number of tumor-
positive cores or increased extent of 
cancer per core
NICE (12) Serum PSA, 3–4 months year 1 post-diagnosis, every 3–6 months 
year 2–4 and then every 6 months, PSA kinetics measured 
throughout AS, DRE every 6–12 months year 1–4 and then annually, 
rebiopsy 12 months after diagnosis or if concern exists about 
clinical or PSA changes, MRI at enrollment f not done, before or in 
the presence of concern about clinical or PSA changes.
Switching recommended if disease 
progression observed, also taking 
into account patient’s life expectancy, 
preferences and comorbidities
GSU (13) Serum PSA every 3 months year 0–3 post-diagnosis, every  
6 months thereafter, PSA kinetics mentioned, DRE every 3 months 
year 0–3 post-diagnosis then every 6 months, if PSA stable 
rebiopsy every 12–18 months within 3 years post-diagnosis, then 
every 3 years
PSA >10 ng/mL, PSA-DT <3 years, tumor 
stage > cT2a, repeat biopsy GS >6, >2 
tumor-positive cores, >50% cancer per 
biopsy core
KCE (14) Serum PSA every 6 months, DRE every 6 months, rebiopsy within 
1-year and repeated thereafter, annual MRI
PSA>10 ng/mL, PSA-DT <3 years, 
clinical change detected during DRE, or 
suspicious lesions on MRI
FCCG (15) Serum PSA, DRE and rebiopsy mentioned PSA-DT <3 years, repeat biopsy GS >6, 
>2 tumor-positive cores, or disease is 
reclassified as clinically relevant
SCAN (16) Serum PSA every 3 months year 1 post-diagnosis, every 6 months 
thereafter, PSA-DT after 5 PSA measurements, DRE ≤6 months, 
repeat biopsy within 6 months post diagnosis then years 1, 4, 7, 
and 10
PSA-DT <3, progression of palpable T2-
stage disease on DRE or palpable lesions 
appearing. GS 4 or 5 at rebiopsy >50% 
spread of cancer in any one core, >50% 
of core samples, or bilateral disease
CCNS (17) Serum PSA every 6 months, DRE every 6 months, rebiopsy at  
6 months if initial biopsy <10 cores or findings discordant with 
clinical findings, within 18 months otherwise, periodically thereafter
Switch recommended at disease 
progression
I+CS (18) Serum PSA every 3 months 0–3 years post-diagnosis, every 6 
months thereafter, PSAV with at least 5 PSA measurements, DRE 
every 3 months within year 0–2 post-diagnosis, every 6 months 
thereafter, rebiopsy year 1, 4, and 7 post-diagnosis
PSAV >1 ng/mL, DRE, rebiopsy GS, 
number of tumor-positive cores, 
maximum extent of cancer per core all 
mentioned
AHS (19) Serum PSA every 3–6 months, PSA kinetics mentioned, DRE 
annually, rebiopsy year 1–2 post-diagnosis, every 2–3 years 
thereafter or as clinically indicated
PSA-DT <3 years, increase clinical stage 
from baseline at DRE, Gleason pattern 
4 or higher, >50% of cancer in any one 
core, patient preferences
CCO (20) Serum PSA every 3–6 months, DRE annually, rebiopsy 6–12 months 
post-diagnosis, every 3–5 years thereafter, MRI mentioned
Repeat biopsy GS ≥7 with pattern 4 
accounting for >10% of the total tumor 
and/or significant increase in tumor volume
PCT (21) Serum-PSA every 6 months, or every 3 months when concern 
of progression, DRE mentioned, PSA kinetics mentioned, repeat 
biopsy within 12 months of initial biopsy or when clinically indicated
NR
Table 1 (continued)
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Table 1 (continued)
Category Monitoring tools Triggers for definitive therapy




Serum PSA every 6 months, DRE every 6 months, rebiopsy every 
12 months
UCSF
Serum PSA every 3 months, DRE every 6 months, rebiopsy every 
12–24 months
MSKCC
Serum PSA every 6 months, DRE every 6 months, rebiopsy every  
3 years, mpMRI every 18 months
MDACC
Serum PSA every 6 months, DRE every 12 months, rebiopsy every 
12–24 months
EU
Serum PSA every 6 months, DRE every 12 months, rebiopsy every 
12 months, mpMRI annually for the first 3 years then final after  
5 years
MUSIC
Serum PSA every 3–6 months, DRE every 12 months, rebiopsy 
every other year, mpMRI every other year and confirmatory test in 
first 3–4 months
Canada
UOFC Serum PSA every 6 months, DRE every 6 months, rebiopsy at  
year 1 then every 2 years, mpMRI when PSA >10 ng/mL
UOFT Serum PSA every 3 months until 2 years, then every 6 months, PSA 
kinetics every 12 months, DRE every 6 months, rebiopsy at year 1, 4, 
7, 10, and 15, mpMRI every 12 months
United Kingdom
GSTT Serum PSA every 6 months, PSA kinetics every 12 months, DRE 
every 12 months, mpMRI every 12 months
UCL Serum PSA 3–4 monthly in year 1 then every 6 months, rebiopsy for 
men with change in MRI and uncertainty about switch to definitive 
therapy, mpMRI at baseline and 12 months the dependent on risk 
factors including MRI, PSA density and GS
Camb Serum PSA every 3 months, rebiopsy within 1 year post-diagnosis, 
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Table 1 (continued)
Category Monitoring tools Triggers for definitive therapy
Europe
KSB
Serum PSA every 6 months, DRE every 6 months, rebiopsy every 
24 months
UCD NR
SU Serum PSA every 3–6 months, DRE every 6–12 months, rebiopsy 
every 2–3 years
Lille-U Serum PSA every 6 months, DRE every 12 months, rebiopsy at 
month 12, mpMRI at month 12
SUS Serum PSA every 3 months, DRE every 6 months, rebiopsy after 
month 12, 48, and 84
INT-MILAN (SAINT) Serum PSA every 3 months, PSA kinetics after first year every  
3 months, DRE every 6 months, rebiopsy every 12 months first 2 
years, then every 24 months
INT-MILAN (PRIAS) Serum PSA every 3 months, PSA kinetics after first year every 3 months, 
DRE every 6 months, rebiopsy after 12, 48, and 84 months
IVO Serum PSA every 6 months, DRE every 6 months, rebiopsy at 
month 6 and 24 then every 3 years, mpMRI before every biopsy
Australasia
MEASCAP Serum PSA every 3 months, DRE every 6 months, rebiopsy  
month 12, 48 and 84
SGH Serum PSA every 3–6 months first 2 years then every 6–12 months, 
PSA kinetics every 12 months, DRE every 12 months, rebiopsy 
every 12 months, mpMRI every 12 months
YUHS Serum PSA every 3 months, rebiopsy considered when change on 
mpMRI is detected, mpMRI every 12 months
KU Serum PSA every 2 months for 6 months then every 3 months, DRE 
every 12 months, rebiopsy every 12 months
Other
PRIAS** Serum PSA every 3 months, PSA kinetics every 6 months, DRE 
every 6 months, rebiopsy after 12, 48, and 84 months
*, Institute abbreviations: JHU, Johns Hopkins University, Baltimore, USA; UCSF, University of California, San Francisco, San Francisco, 
USA; MSKCC, Memorial Sloan Kettering Cancer Center, New York, USA; MDACC, MD Anderson Cancer Centre, Houston, USA; EU, 
Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA; MUSIC, University of Michigan and Michigan Urological 
Surgery Improvement Collaborative, Michigan, USA; UOFC, University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada; 
UOFT, University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada; GSTT, Guy’s and St Thomas’ NHS Foundation Trust, 
London, United Kingdom; UCL, University College London & University College London Hospitals Trust, London, United Kingdom; Camb, 
Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom; KBS, Kantonsspital Baden, Baden, Switzerland; UCD, University 
College Dublin, Dublin , Ireland; SU, Sahlgrenska University Hospital, Göteborg, Sweden; Lille-U, Lille University Hospital Center, Lille, 
France; SUS, Skåne University Hospital, Malmö, Sweden; INT-MILAN, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, 
Italy; IVO, Instituto Valenciano de Oncología, Valencia, Spain; MEASCAP, Monash University and Epworth HealthCare, Melbourne, 
Australia; YUHS, Gangnam Severance Hospital, Yonsei University Health System, Seoul, Republic of Korea; KU, Kagawa University 
Faculty of Medicine, Kagawa, Japan. **, PRIAS (Prostate Cancer Research International Active Surveillance): includes Erasmus Medical 
Center, Rotterdam, the Netherlands; Helsinki University Central Hospital, Helsinki, Finland; University of British Columbia, BC Cancer 
Agency, Vancouver, Canada). ***, NR, not reported.
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Digital rectal examination
All guidelines also recommend the use of DRE as a 
monitoring tool. The majority of the guidelines recommend 
to perform a DRE biannually or annually. One guideline 
recommend a DRE every three months at the start of AS 
and every six months after 2 years on AS (I+CS) or when 
the serum PSA is stable in the first two years (GSU).
DRE is less frequently used as a monitoring tool in the 
studies in the Movember AS database, due to the use of 
multi-parametric magnetic resonance imaging (mpMRI). 
When DRE is used as a monitoring tool it is typically 
performed every 6 or 12 months.
Repeat biopsy scheduling
Repeat TRUS guided biopsy scheduling is recommended 
by all protocols. Repeat biopsy scheduling is included to 
periodically evaluate if disease reclassification has occurred, 
which might influence the prognosis of the patient and is 
the trigger to switch from AS to curative therapy. There 
is substantial variation in biopsy schedules between 
the different guidelines and studies. Most guidelines 
recommend an early repeat biopsy within 1.5 years 
after starting AS. Hereafter, guidelines show substantial 
variation recommending yearly repeat biopsies (NCCN) 
or an early rebiopsy and 2–3 years intervals between later 
repeat biopsies (GSU, SCAN, AHS, CCO). While other 
guidelines mention only an early rebiopsy and make no 
specific recommendations for later repeat biopsies (KCE, 
CCNS, NCCS). One guideline recommends a rebiopsy 
after 1 year and only later repeat biopsies when concern 
rises about clinical and/or serum PSA changes (NICE).
Substantial variation in the frequency and timing of 
the repeat biopsies is also present in the cohorts in the 
Movember AS database. Some cohorts perform a repeat 
biopsy every 1–2 years, and some cohorts perform an early 
rebiopsy (typically after 1 year of starting AS). Two cohorts 
do not routinely perform repeat biopsy, but only if changes 
on mpMRI lead to uncertainty about the decision to switch 
to definitive therapy (UCL) or whenever a change on 
mpMRI is observed (YUHS).
PSA kinetics
Some guidelines recommend the use of PSA kinetics during 
follow-up. Remarkably, none of the clinical guidelines 
mention specific cut-offs to use with PSA kinetics. The 
PRIAS study recommend to perform a repeat biopsy 
whenever the PSA-DT was less than 10 years.
MRI
Four guidelines mention MRI as a possible tool to be used 
in AS. Most suggest that MRI might be used when clinical 
parameters such as PSA, DRE, and PSA kinetics signal 
disease reclassification but results from the repeat biopsy 
are discordant.
Some cohorts in the Movember AS database use the 
mpMRI routinely during follow-up. UCL and YUHS only 
perform repeat biopsies whenever changes on mpMRI 
are observed. Whenever mpMRI is used it is typically 
performed annually. One cohort performed an mpMRI 
before every repeat biopsy (IVO).
Summary of triggers to switch to definitive 
therapy
Most guidelines recommend to switch to definitive 
treatment whenever an increase in Gleason grade is 
detected during AS or if an increase in the number of tumor 
positive cores is detected (>2 of a recommended 10 cores) 
or an increase in the extent of cancer in biopsy cores (>50% 
of cancer per tumor-positive core). Clinical progression 
detected during DRE (although not clearly defined), PSA-
DT <3 years are also mentioned as criteria in five guidelines 
(GSU, KCE, FCCG, SCAN, AHS). Three guidelines 
explicitly mentioned patient preference as a trigger to 
switch treatment. The NICE guidelines also mention that 
comorbidities and life expectancy should be taken into 
account when considering the switch from AS to definitive 
therapy. Triggers for switching to definitive therapy were 
not mentioned in the overview of cohorts in the Movember 
AS database. Currently the guidelines do not mention the 
option to switch from AS to watchful waiting. Watchful 
waiting is similar but distinct to AS, the main difference is 
that in watchful waiting no curative treatment is initiated 
when disease reclassification is detected. Watchful waiting 
may be a viable alternative for patients with low life-
expectancy and/or comorbidities.
Summary of protocolized surveillance
After initiating AS for a patient, most guidelines and 
individual study protocols recommend the use of serum PSA 
measurements, DRE and repeat biopsies as tools to detect 
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progression of the PCa. However there is a wide variation 
in the timing and frequency of the measurements of these 
quantities. Some variation in the definition of progression 
of PCa exists; all guidelines and studies consider an increase 
in Gleason grade as progression. However, progression 
due to increase of the tumor volume is operationalized 
differently between studies and guidelines. MRI and PSA 
kinetics are mentioned less frequently as monitoring tools 
in the guideline, and need further investigation how to best 
use these.
Risk-based dynamic monitoring
Performing a prostate biopsy is a medical burdensome 
procedure. Better scheduling of biopsies might allow for less 
unnecessary procedures and the same benefits of AS. To be 
able to implement risk-based dynamic monitoring schedule a 
prediction model is required that dynamically incorporates all 
relevant information of the patients and provides an estimate 
of the risk of disease reclassification. A major challenge is to 
incorporate the serial measurements of the monitoring tools 
into the prediction model. Three such models have been 
developed recently: the Canary PASS model, Johns Hopkins 
model, and the PRIAS model (Table 2).
Canary-PASS risk calculator
The Canary PASS is an ongoing multicenter prospective and 
observational AS study (22,23). Progression was defined as an 
increase in GS from ≤6 to ≥7 or more than 34% of positive 
biopsy cores at biopsy. Using a cohort of 859 patients, of 
whom 354 (41%) eventually showed disease reclassification, a 
prediction model was developed using logistic regression with 
generalized estimating equations. Reclassification rates varied 
between 11–29% at the different biopsy rounds. Predictors 
included in the prediction model were age at biopsy, time 
since last biopsy, last PSA measurement, percentage of 
tumor-positive cores on the last biopsy and the number of 
tumor-negative biopsies while on AS. The discriminative 
ability of the prediction model was assessed using the area 
under the receiver-operating characteristic (AUC) and was 
equal to 0.74. 
Johns Hopkins post radical prostatectomy 
prediction model
The Johns Hopkins Active Surveillance study is a cohort 
of men who have low-risk PCa according to the Epstein 
criteria (24). A prediction model based on a Bayesian 
hierarchical latent class model was developed to predict the 
GS after a radical prostatectomy (25). The development 
cohort consisted of 964 patients, of whom 195 (20%) 
experienced reclassification after a biopsy and 191 patients 
received radical prostatectomy after opting for active 
treatment. Of these 191 patients, 79 patients had a GS ≥7 
at radical prostatectomy. The developed prediction model 
included the covariates patient age, prostate volume, PSA, 
time since diagnosis, number of previous biopsies, and all 
previous biopsy results. The AUC of the resulting model 
for predicting the GS after RP was 0.74 and the model 
showed reasonable calibration at internal validation.
PRIAS
The PRIAS study is the world’s largest ongoing web-based 
AS study (26). Based on 5,264 patients a Bayesian joint 
model was developed to study the association between the 
evolution of PSA measurements and the risk of Gleason 
grade reclassification (27,28). PSA velocity was found to 
be more strongly associated with the risk of Gleason grade 
reclassification than PSA. Using this model, individual 
predictions could be derived for each patient for progression 
from GS6 to GS ≥7. These predictions are updated as new 
PSA measurements and biopsy results become available. Time-
Table 2 Characteristics of prediction models developed to estimate the risk of disease reclassification during AS
Prediction model Statistical technique Development population Endpoint
Canary-PASS Generalized estimating 
equations (GEE)
859 patients from the Canary-PASS 
cohort
GS ≥7 or ≥34% of tumor-positive 
cores
Johns Hopkins Bayesian hierarchical latent 
class model
964 patients from Johns Hopkins GS ≥7 at radical prostatectomy
PRIAS Joint model* 5,624 patients from the PRIAS project Time until GS ≥7 at biopsy
*, a combination of a mixed effect model and a survival model. AS, active surveillance.
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varying AUCs at year 1, 2 and 3 were only moderate (0.61, 
0.66, and 0.60 respectively, for a time window of 1 year) (29).
Protocol based monitoring versus risk-based 
monitoring
A number of studies have aimed to compare the impact of 
different fixed follow-up schedules on patient outcomes. 
Using data from the Johns Hopkins cohort, delay in 
detection of disease reclassification and the reduction in the 
number of biopsies was compared if the PRIAS protocol 
was applied in these patients (30). It was found that using 
the PRIAS protocol would lead to a median delay in 
detection time of 1.9 years.
Several simulation studies have been performed aiming 
to estimate the trade-off between the reduction in number 
of biopsies taken and the delay in detection of disease 
reclassification (31-33). Although all studies used different 
modelling strategies, two studies used data from the Johns 
Hopkins cohort to calibrate their models (33,34). Both 
these studies concluded that switching from yearly biopsies 
to less frequent biopsies would lead to a relatively modest 
increase in delay of detection of the disease reclassification. 
The third simulation study used data from Johns Hopkins, 
Canary Prostate Active Surveillance Study, University of 
California, San Francisco, and University of Toronto. A delay 
in detection of disease reclassification of 3-5 months was 
estimated when switching from yearly to biennial biopsies.
Another study used simulations to compare the 
consequences of protocol based screening versus risk-based 
dynamic monitoring using patient data from PRIAS (28). 
The time to Gleason score upgrading of the PCa was 
estimated using joint models, taking into account the results 
from PSA tests and previous biopsy results. A risk-based 
dynamic monitoring approach was compared to the Johns 
Hopkins follow-up schedule and the PRIAS schedule. It 
was found that the risk based dynamic monitoring approach 
could potentially reduce the average number of biopsies 
taken during follow-up from 5 to 2, at the price of increasing 
the time between disease reclassification and the detection of 
upgrading from 6–8 months to approximately 14 months. No 
major difference in the number of biopsy taken and the delay 
in detection of the disease reclassification was found between 
the Johns Hopkins and PRIAS schedule.
Discussion
Currently few models are available to predict the risk of 
disease reclassification reliably during follow-up in AS. 
Whenever models have been developed thorough external 
validation of these models is lacking. Several simulation 
studies have been performed comparing more strict and 
more relaxed follow-up schedules. These have illustrated 
the trade-off between the number of biopsies taken and the 
delay in detection of disease progression. These simulation 
studies suggested that a yearly schedule could be relaxed to 
a biennial or triennial follow-up schedule without a large 
increase in delay of PCa detection, although a formal risk-
benefit analysis is needed for firmer conclusions.
A recent microsimulation study investigated the optimal 
age at which AS should be stopped. After such an age, 
further biopsies would provide no further benefit, indicating 
that a switch to watchful waiting is warranted (31). The 
optimal age at which to stop AS was strongly dependent 
on the disease risk and life expectancy of a patient. Most 
guidelines and currently proposed prediction models do not 
consider life expectancy explicitly in recommendations for 
switching from AS to definitive therapy. Life-expectancy 
may modeled using a competing risk analysis, where 
death due to other causes is a competing risk to disease 
progression.
The majority of the cohorts containing AS patients are 
observational cohorts. Developing prediction models using 
observational data runs the risk of introducing biases from 
the dataset into the prediction model. In the context of AS 
cohorts this is present in the form of ascertainment bias, 
patients who are at high risk of progression receive more 
biopsies and hence are detected earlier. For instance, some 
guidelines recommend to do a biopsy if the PSA-DT is too 
short. Most statistical methods provide unbiased estimates 
as long as all relevant patient and tumor characteristics are 
entered in the prediction model that is used in the decision 
to take a biopsy. Having such a statistically correct model is 
a rather strong assumption.
The vast majority of AS schedules use PSA and DRE 
measurements as a surveillance tool. There is an increasing 
interest in the use of mpMRI in AS as a tool to reduce 
the number of biopsies (35). Additionally, various blood 
biomarkers are investigated as monitoring tools in AS 
(36,37). These markers can potentially improve the 
previously developed prediction models and may further 
reduce the number of biopsies required to detect a disease 
reclassification and/or the delay in the detection of disease 
reclassification. External validation across a range of setting 
is required before clinical application of such models is 
considered (38,39).
114
Transl Androl Urol 2018;7(1):106-115tau.amegroups.com© Translational Andrology and Urology. All rights reserved.
Nieboer et al. Risk-based dynamic monitoring
In conclusion, risk-based dynamic monitoring is a 
promising alternative to a fixed follow-up schedule for all 
patients in AS. Simulation studies have shown that the 
number of biopsies required to detect disease reclassification 
could be reduced at the price a limited delay in detection 
of the disease reclassification. External validation of the 
proposed prediction models is currently lacking and is 
essential before implementing these dynamic prediction 
models into clinical practice.
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